Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galvokimig
- Development stage
- Phase 2
- Lead developer
- UCB
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Galvokimig (formerly known as UCB9741 or UCB-9741) is a trispecific monoclonal antibody developed by UCB Biopharma for the treatment of atopic dermatitis. It targets and inhibits interleukin-13 (IL-13), interleukin-17A (IL-17A), and interleukin-17F (IL-17F), which are key mediators of inflammation in atopic dermatitis. The drug is administered intravenously or subcutaneously and has been evaluated in phase I/II clinical trials to assess its safety, pharmacokinetics, immunogenicity, and efficacy in both healthy volunteers and patients with moderate-to-severe atopic dermatitis[1][2][3][6][8].
- Other names
- galvokimigUCB 9741UCB9741UCB-9741
02
Targets
IL-17A (Interleukin-17A)IL17F (Interleukin 17F)IL-13 (Interleukin-13)
Beyond the preview
Go deeper on galvokimig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galvokimig.